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Previous studies of congenital hypothyroidism have suggested an increasing incidence and seasonal variation in incidence, which
may suggest nongenetic factors involved in aetiology. This study describes the incidence of elevated thyroid stimulating hormone
(TSH)valuesinnewborns,asurrogateforcongenitalhypothyroidism,measuredaspartofthescreeningprogrammeforcongenital
hypothyroidism, over an eleven-year period (1994–2005), and assesses whether seasonal variation exists. All infants born in the
Northern Region of England are screened by measuring levels of circulating TSH using a blood spot assay. Data on all 213 cases
born from 1994 to 2005 inclusive were available. Annual incidence increased signiﬁcantly from 37 per 100,000 in 1994 to a peak
of 92.8 per 100,000 in 2003. There was no evidence of seasonal variation in incidence. The reasons for the increasing incidence are
unclear, but do not appear to involve increasing exposure to seasonally varying factors or changes in measurements methods.
1.Introduction
Congenital hypothyroidism (CHT) is the most common
congenital endocrine disorder with a world-wide incidence
around 1 in 3500 to 4000 live births. Reduced thyroid
hormone production in babies with CHT has a major
detrimental eﬀect on central nervous system development
and growth. Prompt treatment with thyroxine will prevent
these problems arising in the majority of babies.
Most babies with CHT have thyroid gland agenesis or
dysgenesis with a poorly formed or absent gland. A minority
(∼20%) have a normally sited gland but an underlying
single gene defect preventing the normal process of thyroid
hormone production within the gland (dyshormonogene-
sis). Although germline mutations in thyroid transcription
factors 1 and 2 (TTF-1 and TTF-2) and PAX-8 (paired
box transcription-8) have been identiﬁed as aetiological risk
factors for dysgenesis or agenesis, they only explain a small
percentage of cases (around 2%) [1]. It is important to
highlight the fact that iodine deﬁciency is a well recognised
andimportantcauseofneonatalthyroiddysfunctioninsome
parts of the world.
An increasing incidence of CHT has been suggested
from an analysis of data including that from New York
State [2]a n dM e x i c o[ 3], although no similar increase was
shown in a similar study of data from Quebec [4]. Previous
studies in the United Kingdom have suggested that CHT is
more prevalent in Asian sectors of the population and that
prevalence has increased [5]. Studies also suggest that the
prevalence of hypothyroidism in Scotland has increased [6],
with a study from the same area of Scotland demonstrat-
ing an increased population prevalence of hypothyroidism
in young people compared to previously published rates
[7].
The incidence of CHT has also been suggested to vary
seasonally in a number of studies in diﬀerent geographical2 Journal of Thyroid Research
areas including the West Midlands of England [5], Finland
[8], Japan [9–11], and Australia [9]. However, seasonality
also has been not observed in a number of other studies,
including those in the North West of England [12], the
Netherlands [13], Saudi Arabia [14], Canada [4], Norway,
France and Switzerland [9].
Should seasonal variation in CHT risk exist, this would
suggest that an unknown environmental factor may be
involved in the disease’s aetiology. Temporal trends in risk
are usually unlikely to include genetic factors, unless either
population shifts result in germline mutations being more
prominent in a particular geographical area or environmen-
tal inﬂuences on germline mutations or epigenetic changes
have increased in prevalence over the study period.
Circulating thyroid stimulating hormone (TSH) levels
are measured as part of screening programmes for CHT
across many parts of Europe, Japan, and increasingly in
North America. In the UK, neonatal screening for CHT
began in 1979 in Scotland and in 1981 in the remainder of
the UK after a recommendation from the UK Department of
Health [15].
This paper describes the incidence of elevated TSH
levels in newborns in the North of England over an eleven-
year period (1994–2005) and examines whether seasonal
variation in incidence exists in this geographical area.
2. Methods
Around 35000 infants in the Northern Region of England,
comprising North East England (the area from Teesside
extending north into Northumberland) and North Cumbria,
are screened every year in a single centre by measuring blood
spot TSH levels. Data on all cases, including dates of birth,
were available from 1994 to 2005 inclusive.
2.1. TSH as a Surrogate for CHT. We opted to refer to “TSH”
rather than “CHT” in this study for the following reasons.
(1) The extent to which cases of suspected CHT are
investigated will vary from one unit to another [16,
17]. We felt that this was likely to be the case in our
region of the UK as well.
(2) There is no deﬁnitive test or tests that can identify
the underlying thyroid gland abnormality in this
condition. Even the combination of isotope scanning
and ultrasonography does not reveal an underlying
diagnosis in all infants [16, 18].
(3) The sensitivity and speciﬁcity of tests such as isotope
scanning is suboptimal with potentially misleading
information generated by factors such as early thy-
roxine therapy [18].
(4) Some studies have used thyroxine intervention as
conﬁrmation of underlying CHT but the threshold
for intervention will vary with time and from clin-
ician to clinician and centre to centre [19]. Hence
some babies with “raised” TSH values and thyroid
hormone values within the laboratory normal range
will be treated whilst others will not [5, 16].
(5) Ultimately, biochemistry is the most important
parameter; a baby with a raised TSH but normal
imaging will require thyroxine treatment whilst a
baby with normal biochemistry but abnormal imag-
ing will not.
2.2. Sample Processing andAnalysis. During the period of the
study the screening centre moved between the Royal Victoria
Inﬁrmary (RVI), Newcastle and the University Hospital of
North Durham (UHND), Durham. The screening blood
spot TSH method and cut-oﬀ value for screening failure also
changed during the study from a manual radioimmunassay
method (1994–March 1998) to an ACS-(Beyer) chemilu-
minometric assay (April 1998–February 2003) and then a
DELFIA (perkin Elmer) ﬂuoroimmunometric assay (March
2003–present) (Table 1).
Interassay coeﬃcients of variation (CV) for blood spot
TSH assays were 16.5%, 9.4%, and 8.8% for the manual
radioimmun assay method at TSH values of 22.0, 38.6, and
74.1mU/L, respectively. Interassay CV for blood spot TSH
assays were 7% and 6% for the ACS chemiluminometric
assay at TSH values of 14mU/L and 68mU/L, respectively,
and 11% and 12% for the DELFIA ﬂuoroimmunometric
assay at TSH values of 16mU/L and 60mU/L, respectively.
Nine replicates over 9 analytical runs were used to calculate
inter assay precision for the ACS assay and 42 replicates over
10 analytical runs for the DELFIA assay. To ensure that cut-
oﬀ values were comparable across the diﬀerent screening
methods used, prior to a change in method blood spot
samples received as part of the screening program were
analysed by both methods (Radioimmunoassay v ACS-180,
n = 2634; ACS-180 v DELFIA, n = 682). Revised cut-oﬀ
valueswereestablishedbycomparingtheresultsusingscatter
charts and using least squares linear regression. There was a
highly signiﬁcant correlation between the 2 methods when
the assay was changed from RIA to ACS-180 in 1998 (P<
.001; r2 = 0.94) and when it was changed from ACS-180 to
DELFIA in 2003 (P<. 001; r2 = 0.99). 100% agreement for
screening passes and failures was obtained using the revised
cut-oﬀ values.
Values identiﬁed as being greater than 20mU/L by the
radioimmunassaymethod,10mU/LbytheACSmethod,and
greater than 6mU/L by the DELFIA method were followed
by analysis of a repeat blood spot from the screening card.
They were deemed to be screening failures if the ﬁnal
blood spot value was again greater than 10mU/L (ACS) or
6mU/L (DELFIA). All infants where the paediatrician was
subsequently notiﬁed of an increased value and hence were
classed as neonatal screening test failures were included in
the analysis.
2.3. Statistical Analysis. The yearly incidence of elevated
TSH values in newborns was calculated as the number
of cases in each year per 100,000 live births born in
the Northern Region. Temporal changes in incidence were
assessed using Poisson regression. Seasonal variation in
incidence was assessed using the Edwards test for seasonality
[20] with an adjustment for variable month length. A P-
value of less than .05 was considered statistically signiﬁcant.Journal of Thyroid Research 3
Table 1: TSH newborn screening base, assay methodology, and cut-oﬀ values during the study period.
1994–March 1998 April 1998–February
2003
March 2003–March
2005 April 2005–present
Centre Newcastle Durham Durham Newcastle
Method Radioimmunoassay ACS-180 DELFIA DELFIA
(Manual) (Bayer) (Perkin Elmer) (Perkin Elmer)
TSH cut-oﬀ (mU/L) 20 10 6 6
Table 2: Annual number of cases and incidence of elevated TSH
levels on newborn screening in the Northern Region of England,
1994–2005.
Year Number of cases Incidence per
100,000 live births
1994 15 37.12
1995 11 32.26
1996 13 38.61
1997 5 15.21
1998 16 49.99
1999 20 64.65
2000 15 50.63
2001 22 76.11
2002 26 89.02
2003 28 92.84
2004 22 70.93
2005 20 63.64
All statistical analyses were performed using the statistical
software package Stata, version 9.0 (StataCorp, Texas).
Approvals for this study were obtained from the Newcas-
tleandNorthTynesideLocalResearchEthicsCommitteeand
the Patient Information Advisory Group for England and
Wales.
3. Results
Between 1994 and 2005 inclusive, there were 213 cases of
elevated TSH values in newborns in the Northern Region
of England. The ratio of female to male cases was 1.3:1 .
Over the study period, the average annual incidence was
59.94 per 100,000 live births. The annual number of cases
of TSH elevation in newborns in the Northern Region and
annualincidenceper100,000livebirthsareshowninTable 2.
Incidence increased signiﬁcantly over the study period (P<
.0001) from 37 per 100,000 in 1994 to a peak of 92.8i n
2003.
The number of cases by month of birth is reported in
Table 3. Despite peak number of cases in May and in the
August–October period, there was no signiﬁcant evidence of
seasonal variation in the number of cases (P = .16). Nor
was there evidence of seasonal variation with sex-speciﬁc
seasonality analyses (P = .17 for females and 0.59 for males).
Table 3: Number of cases of elevated TSH levels on newborn
screening by month of birth in the Northern Region of England,
1994–2005.
Month Number of cases
January 14
February 14
March 14
April 17
May 25
June 19
July 16
August 20
September 23
October 20
November 16
December 15
4. Discussion
Despite advances made in identifying genetic risk markers
for CHT, there remains a great deal to be explained in terms
of the aetiology of the disease [21]. This study showed an
increasing incidence of elevated TSH values in newborns in
the Northern Region of England between 1994 and 2005, but
did not ﬁnd evidence of seasonal variation in the number
of cases. Many other studies have depended primarily on
biochemistry including TSH rather than other investigations
when making a diagnosis of CHT [22]. Given the high risk
ofsubclinicalhypothyroidismandmorphologicalabnormal-
ities in “false-positive” patients [23, 24] we suspect that our
ﬁgures for raised TSH will be closely linked to the number
of actual cases of CHT. Unfortunately we do not have
detailed information on outcome in these children because
they were managed in more than 10 diﬀerent hospitals by
an even greater number of clinicians. More detailed data
were therefore not available to allow us to assess changes
in permanent CHT or to analyse the data with respect to
diﬀerent aetiologies.
An increasing temporal trend in incidence of CHT
has recently been reported in New York State [2], with a
138% increase between 1978 and 2005. Excluding New York
State, nationwide United States data suggest a 73% increase
between1987and2002[22].Weobserveda151%increasein
raised TSH values between 1994 and 2003. However, this is4 Journal of Thyroid Research
in contrast to research conducted in Quebec, Canada, where
no changes in incidence were seen over a 16-year period
[4]. A real temporal trend, aside from changes in diagnostic
procedures which can lead to increases in incidence [25],
suggests either an increasing exposure to an environmental
risk factor, or a changing distribution of risk factors among
the population. The incidence rates in this study dropped
slightly after 2003 and it remains to be seen whether this is
a true decline or simply random variation.
The division between a “screen positive” and “screen
negative” in a screening programme such as this is not linked
to robust outcome measures and the screening threshold
and management of cases with mild thyroid dysfunction
varies between regions. We were keen to establish that the
change in incidence was not simply a reﬂection of change
in assay methodology or laboratory practice (as opposed
to seasonality where we would not expect assay change to
have the same impact). All births in the study region were
screened in a single centre at any one time. The physical
location of this centre changed originally in April 1998 from
Newcastle to Durham and again in April 2005 from Durham
to Newcastle. The move in 1998 also corresponded to a
change in the laboratory assay with a further change in
assay in 2003. The diﬀerent assay methods were rigorously
compared to ensure that there would be no diﬀerence in
the number of cases identiﬁed as a result of the change.
To this end a large number of samples were analysed and
there was no diﬀerence in screening passes or failures with
100% concordance. It is of note that the increasing incidence
in raised TSH values was most striking during the period
when TSH was measured only by the ACS method although
we suspect that this represents a true increase because the
rise had commenced prior to the change in methodology
and continued after this changed to the DELFIA assay.
Many other studies of CHT or elevated TSH levels have
encountered similar issues regarding data interpretation as
assay methodology has changed [16].
In terms of changes in the population structure, two
previous studies from England have reported an increased
incidence of CHT among Asians [5, 12]. However, the
Northern Region of England has a population of 3.1 million,
of which less than 2% are from ethnic minorities, with low
levels of migration [26]. Therefore, while the data are not
available to assess directly, it is unlikely that the increased
incidence is related to changes in population structure and
with it changes in genetic risk factor proﬁles. Exposure to
environmental factors such as chemicals or increasing levels
of other risk factors such as maternal iodine deﬁciency or
high prenatal iodine exposures [27]o rl o wb i r t hw e i g h t
infants [28] may be suggested by an increasing temporal
trend whereasinfections or seasonally varying dietary factors
or chemical exposures, such as dioxin and polychlorinated
biphenyl [29], may be suggested by evidence of seasonal
variation in the number of cases. The potential role of a
suboptimal maternal iodine status in some parts of the
North of England should be highlighted and clearly warrants
further study [30]. We found little evidence of seasonal
variation of elevated TSH levels in newborns, in line with a
number of previous reports of no seasonality [4, 9, 12–14].
In contrast, a number of previous studies have reported
seasonalvariationinanumberofdiﬀerentgeographicalareas
[5, 8–11], including a diﬀerent part of England [5]. Gu
et al. also found sex-speciﬁc seasonal patterns of incidence
in Japan [31]. However, sex-speciﬁc analyses also showed
little evidence of seasonal variation in this study. The issue
of statistical power should be considered when interpreting
our results and it is possible that with a larger sample a
seasonal eﬀect may have been found. It is also possible
that diﬀerences in ﬁndings may reﬂect diﬀerences in the
underlying populations. Our sex ratio (F : M) of 1.3:1w a s
signiﬁcantlylessthanthesexratioof2.8 : 1previouslyshown
in a study from Scotland that used thyroxine prescription
dataasasurrogateforhypothyroidisminchildrenandyoung
people [7] and less than the ratio of 2.1 : 1 reported for cases
of “true” CHT from the same country [16]. This underlines
the importance of taking factors such as iodine status into
consideration in future work.
In conclusion, we have observed a signiﬁcant increasing
trend in the incidence of elevated TSH levels in newborns,
a surrogate for increasing levels of CHT, since 1994. Whilst
the reasons for the increase are unclear, it would appear from
this analysis that seasonally varying factors are not involved.
It is also unlikely to be due to a change in the population
distribution of genetic risk factors, although environmental
determinants of genetic mutations and epigenetic factors
cannot be ruled out. Further research is required into the
potential environmental determinants of increased CHT
risk.
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